Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.
Aparicio J, García del Muro X, Maroto P, Paz-Ares L, Alba E, Sáenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sánchez M, Fernández A, Sastre J, Carles J, Dorca J, Gumà J, Yuste AL, Germà JR; Spanish Germ Cell Cancer Cooperative Group (GG). Aparicio J, et al. Among authors: maroto p. Ann Oncol. 2003 Jun;14(6):867-72. doi: 10.1093/annonc/mdg241. Ann Oncol. 2003. PMID: 12796024 Free article.
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Roldán-Romero JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez-Montes A, Monteagudo M, Mellid S, Leandro-García LJ, Montero-Conde C, Cascón A, Roncador G, Coloma J, Robledo M, Rodriguez-Antona C. Roldán-Romero JM, et al. Among authors: maroto p. Int J Cancer. 2023 Sep 15;153(6):1300-1312. doi: 10.1002/ijc.34575. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260183
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
Climent MÁ, Álvarez C, Morales R, Maroto P, Rodríguez-Vida A, Méndez-Vidal MJ, Del Muro XG, Puente J, Láinez N, Vázquez S, Castellano D, Lang CG, Wang J, di Pietro A, Davis C, Sanz-Castillo B, Bolós MV, Valderrama BP. Climent MÁ, et al. Among authors: maroto p. Clin Transl Oncol. 2024 Jun;26(6):1532-1538. doi: 10.1007/s12094-023-03358-4. Epub 2023 Dec 15. Clin Transl Oncol. 2024. PMID: 38102374 Free PMC article. Clinical Trial.
[Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP].
López-Beltrán A, González-Peramato P, Sanz-Ortega J, Prieto Cuadra JD, Trias I, Luque Barona RJ, Semidey ME, Maroto P, Algaba F. López-Beltrán A, et al. Among authors: maroto p. Rev Esp Patol. 2023 Oct-Dec;56(4):261-270. doi: 10.1016/j.patol.2023.05.001. Epub 2023 Sep 1. Rev Esp Patol. 2023. PMID: 37879823 Review. Spanish.
Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).
Germà-Lluch JR, Garcia del Muro X, Maroto P, Paz-Ares L, Arranz JA, Gumà J, Alba E, Sastre J, Aparicio J, Fernández A, Barnadas A, Terrassa J, Sáenz A, Almenar D, López-Brea M, Climent MA, Sánchez MA, Lasso de la Vega R, Berenguer G, Pérez X; Spanish Germ-Cell Cancer Group (GG). Germà-Lluch JR, et al. Among authors: maroto p. Eur Urol. 2002 Dec;42(6):553-62; discussion 562-3. doi: 10.1016/s0302-2838(02)00439-6. Eur Urol. 2002. PMID: 12477650
110 results